A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination With a PI or NNRTI in Antiretroviral Experienced Patients.
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2011
At a glance
- Drugs Abacavir; Antiretrovirals; Lamivudine; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 24 Mar 2009 Investigational drugs identified as reported by ClinicalTrials.gov.
- 12 Jun 2007 Status changed from in progress to completed.
- 11 Oct 2005 New trial record.